Atossa Therapeutics, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 2.17 USD (Oct 30, 2026, 4:00 PM EST) · Market cap 21.66M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.
Details
| Name | Atossa Therapeutics, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 16 |
| Founded | 2009 |
| Ipo Date | 2012-11-08 |
| Ceo | Steven Quay |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US04962H7044 |
| Cusip | 04962H704 |
| Cik | 0001488039 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Steven C. Quay FCAP, M.D., Ph.D. | Chairman, Chief Executive Officer and President |
| Mark J. Daniel CPA | Chief Financial Officer |
| Janet Rose Rea MSPH, RAC | Senior Vice President of Research and Development |
| Delly Behen P.H.R. | Senior Vice President of Business Operations |
| Dr. Richard Graydon M.D., Ph.D. | Interim Chief Medical Officer |
Contact
| Address | 448 NW Market Street, Suite 500, Seattle, Washington 98107, United States |
| Phone | 206 588 0256 |
| Website | https://www.atossatherapeutics.com |